Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges (2016 - 2025)

Ligand Pharmaceuticals' Amortization of Deferred Charges history spans 14 years, with the latest figure at $565000.0 for Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 228.49% year-over-year to $565000.0; the TTM value through Dec 2025 reached $1.3 million, up 161.93%, while the annual FY2025 figure was $1.3 million, 161.93% up from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $565000.0 at Ligand Pharmaceuticals, up from $447000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $4.9 million in Q1 2021 and bottomed at $64000.0 in Q2 2023.
  • The 5-year median for Amortization of Deferred Charges is $138000.0 (2022), against an average of $1.0 million.
  • The largest annual shift saw Amortization of Deferred Charges plummeted 97.52% in 2022 before it surged 233.58% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $3.8 million in 2021, then tumbled by 97.52% to $95000.0 in 2022, then fell by 14.74% to $81000.0 in 2023, then soared by 112.35% to $172000.0 in 2024, then soared by 228.49% to $565000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Amortization of Deferred Charges are $565000.0 (Q4 2025), $447000.0 (Q3 2025), and $125000.0 (Q2 2025).